◆ Market Terminal AILook up a stock

Vericel Corporation (VCEL)

Healthcare · Biotechnology · Mid-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Vericel Corporation is a strong business by our measures, its shares look expensive compared with other stocks, and its share price trend is middling.
Value34
Quality68
Price trend48
Overall47
1739 of 2764rank among the US stocks we score (our core model buys the top 15)
37%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$276.3M
Sales growthchange from the year before+16.5%
Gross marginshare of sales left after the direct cost of what it sells74.4%
Operating marginshare of sales left after running the business4.0%
Net marginshare of sales kept as profit6.0%
Free-cash-flow marginspare cash generated per $100 of sales9.0%
Return on invested capitalprofit made on each $100 put into the business2.5%
Return on equityprofit vs. shareholders' accounting value4.7%
Change in share countnegative = the company is buying back its shares+0.9%

Insider trades, last 90 days

2 insiders sold $688K (all under pre-arranged plans) on the open market.

Halpin MichaelChief Operating OfficerSold (plan)Aug 310,000 shat $46.84 · $468K
Siegal JonathanPrincipal Accounting OfficerSold (plan)Jul 304,500 shat $48.90 · $220K

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy